Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.467NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
B.1.1.484NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
B.1.476NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
A.19NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
A.18NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
B.1.1.404NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
CV.2NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
DJ.1.3NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BQ.1.1.73NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
DW.1NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BR.5.1NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BA.2.75.3NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
XAKNWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
XAANWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BQ.1.30NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BQ.1.1.50NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BA.5.1.36NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
XBB.1.23NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
XBB.1.38.1NWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
N/ANWon-NCAATGCTGCAATCGTGCTAC20502873228751F-22388.1South Korea
BQ.1.30NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BQ.1.1.50NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BA.5.1.36NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XBB.1.23NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XBB.1.38.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
N/ANUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AY.42.1 (Delta)NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.348NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.428.2NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
AJ.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.459NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.160.29NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.415.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.243.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.98NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.566NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.1.480NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.579NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
N.10NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
P.1.11 (Gamma)NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.435NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.445NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.124NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.384NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
XAQNUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
BA.2.3.8NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.569NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.524NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
A.23NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.596.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used